AVDL vs. NUVL, TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, and ADMA
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs. Its Competitors
Nuvalent (NASDAQ:NUVL) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.
Avadel Pharmaceuticals has higher revenue and earnings than Nuvalent. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
Nuvalent has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Nuvalent's return on equity.
Nuvalent has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
In the previous week, Nuvalent and Nuvalent both had 7 articles in the media. Avadel Pharmaceuticals' average media sentiment score of 1.37 beat Nuvalent's score of 1.04 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Nuvalent currently has a consensus price target of $119.50, indicating a potential upside of 50.53%. Avadel Pharmaceuticals has a consensus price target of $20.86, indicating a potential upside of 34.34%. Given Nuvalent's higher probable upside, analysts clearly believe Nuvalent is more favorable than Avadel Pharmaceuticals.
Summary
Avadel Pharmaceuticals beats Nuvalent on 9 of the 15 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 9/16/2025 by MarketBeat.com Staff
Free AVDL Stock Alerts